Pfizer faces revenue decline from patent expirations, profitability challenges, and bearish technicals. Learn why PFE stock ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...

In the chart below, we zoom in on the ... This risk is higher in a company without a history of growth. You can see Pfizer's historic earnings and revenue below, but keep in mind there's always ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $30.0 for Pfizer during the past quarter. Looking at the volume ...

Pfizer Inc. (NYSE:PFE – Get Free Report) shares traded up 2.9% on Wednesday following a stronger than expected earnings report. The company traded as high as $26.69 and last traded at $26.62.

The company is actively working on its obesity program, with updates expected in early 2025. This commitment to developing its danuglipron program is a significant factor, as Pfizer is making ...

A look at the shareholders of Pfizer Inc. (NYSE:PFE) can tell us which group is most powerful. The group holding the most ...

Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance ... reveals his one-line chart technique that shows when ...